Target Information

Target General Infomation
Target ID
T22977
Former ID
TTDR00265
Target Name
Superoxide dismutase [Cu-Zn]
Gene Name
SOD1
Synonyms
Superoxide dismutase; SOD1
Target Type
Clinical Trial
Disease Dermatitis [ICD9: 692.9; ICD10: L20-L30]
Motor neurone disease [ICD9: 335.2; ICD10: G12.2]
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Function
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
BioChemical Class
Oxidoreductases acting on superoxide as acceptor
UniProt ID
P00441
EC Number
EC 1.15.1.1
Sequence
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV
HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ
Structure
1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO; 2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD; 1AZV; 1BA9; 1DSW; 1FUN; 1HL4; 1HL5; 1KMG; 1L3N; 1MFM; 1N18; 1N19; 1OEZ; 1OZT; 1OZU; 1P1V; 1PTZ; 1PU0; 1RK7; 1SOS; 1SPD; 1UXL; 1UXM; 2AF2; 2C9S; 2C9U; 2C9V; 2GBT; 2GBU; 2GBV; 2LU5; 2NNX; 2R27; 2V0A; 2VR6; 2VR7; 2VR8; 2WKO;2WYT; 2WYZ; 2WZ0; 2WZ5; 2WZ6; 2XJK; 2XJL; 2ZKW; 2ZKX; 2ZKY; 3CQP; 3CQQ; 3ECU; 3ECV; 3ECW; 3GQF; 3GTV; 3GZO; 3GZP; 3GZQ; 3H2P; 3H2Q; 3HFF; 3K91; 3KH3; 3KH4; 3LTV; 3QQD; 3RE0; 3T5W; 4A7G; 4A7Q; 4A7S; 4A7T; 4A7U; 4A7V; 4B3E; 4BCY; 4BCZ; 4BD4; 4FF9; 4MCM; 4MCN; 4NIN; 4NIO; 4NIP; 4OH2; 4SOD
Drugs and Mode of Action
Drug(s) Coprexa Drug Info Phase 3 Neurological disease [528378]
ATN-224 Drug Info Phase 2 Solid tumours [521926]
Methoxyestradiol Drug Info Phase 2 Discovery agent [522202]
APN-201 Drug Info Phase 1/2 Dermatitis [523766]
Inhibitor Acetate Ion Drug Info [551393]
ATN-224 Drug Info [528378]
Coprexa Drug Info [528378]
Methoxyestradiol Drug Info [535595]
S-Oxy Cysteine Drug Info [551391]
TDI-0107 Drug Info [528378]
Modulator APN-201 Drug Info [525361]
TDI-0060 Drug Info [528378]
TDI-0079 Drug Info [528378]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
BioCyc Pathway Reactive oxygen species degradation
KEGG Pathway Peroxisome
Amyotrophic lateral sclerosis (ALS)
Huntington&#039
s disease
Prion diseases
NetPath Pathway TCR Signaling Pathway
Pathway Interaction Database Validated nuclear estrogen receptor alpha network
FOXA1 transcription factor network
PathWhiz Pathway Degradation of Superoxides
Reactome Platelet degranulation
Detoxification of Reactive Oxygen Species
WikiPathways Oxidative Stress
Copper homeostasis
Detoxification of Reactive Oxygen Species
Nifedipine Activity
Amyotrophic lateral sclerosis (ALS)
Dopamine metabolism
AGE/RAGE pathway
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 521926ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 522202ClinicalTrials.gov (NCT00592579) A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma. U.S. National Institutes of Health.
Ref 523766ClinicalTrials.gov (NCT01513278) Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer. U.S. NationalInstitutes of Health.
Ref 528378Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
Ref 525361Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. doi: 10.1038/ijir.2008.30. Epub 2008 Jul 24.
Ref 528378Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
Ref 535595Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. Epub 2002 Oct 29.
Ref 551391DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-4. Nucleic Acids Res. 2011 January
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.